- Home
- THAR vs ALLR Comparison
THAR vs ALLR Comparison
Compare THAR & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- ALLR
- Stock Information
- Founded
- THAR 2017
- ALLR 2004
- Country
- THAR United States
- ALLR United States
- Employees
- THAR N/A
- ALLR N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- ALLR Health Care
- Exchange
- THAR Nasdaq
- ALLR Nasdaq
- Market Cap
- THAR 4.0M
- ALLR 4.0M
- IPO Year
- THAR 2022
- ALLR N/A
- Fundamental
- Price
- THAR $1.25
- ALLR $0.82
- Analyst Decision
- THAR Strong Buy
- ALLR
- Analyst Count
- THAR 1
- ALLR 0
- Target Price
- THAR $17.00
- ALLR N/A
- AVG Volume (30 Days)
- THAR 135.2K
- ALLR 2.6M
- Earning Date
- THAR 05-08-2025
- ALLR 05-13-2025
- Dividend Yield
- THAR N/A
- ALLR N/A
- EPS Growth
- THAR N/A
- ALLR N/A
- EPS
- THAR N/A
- ALLR N/A
- Revenue
- THAR N/A
- ALLR N/A
- Revenue This Year
- THAR N/A
- ALLR N/A
- Revenue Next Year
- THAR N/A
- ALLR N/A
- P/E Ratio
- THAR N/A
- ALLR N/A
- Revenue Growth
- THAR N/A
- ALLR N/A
- 52 Week Low
- THAR $1.20
- ALLR $0.68
- 52 Week High
- THAR $7.13
- ALLR $174.00
- Technical
- Relative Strength Index (RSI)
- THAR 32.14
- ALLR 37.39
- Support Level
- THAR $1.20
- ALLR $0.91
- Resistance Level
- THAR $1.47
- ALLR $1.23
- Average True Range (ATR)
- THAR 0.15
- ALLR 0.14
- MACD
- THAR -0.01
- ALLR -0.02
- Stochastic Oscillator
- THAR 2.04
- ALLR 3.15
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.